Bluejay Diagnostics, Inc.

BJDX ·Healthcare, Medical Devices, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Operating Activities
Net Income $-6.8M $-7.7M $-10.0M $-9.3M $-3.5M $-1.2M
Depreciation & Amortization — — — $156.6K $145.7K $157.0K
Depreciation $74.2K $75.6K $648.7K $156.6K — —
Amortization — — — — — —
Stock-Based Compensation $6 $20.1K $189.2K $433.0K $68.5K $3.7K
Net Cash from Operating Activities $-6.1M $-7.8M $-8.3M $-7.7M $-4.4M $-508.7K
Investing Activities
Capital Expenditures $173.7K $306.8K $704.2K $1.2M $23.9K —
Business Acquisitions — — — — — —
Net Cash from Investing Activities $-173.7K $-306.8K $-704.2K $-1.2M $-23.9K —
Financing Activities
Dividends Paid — — — — — —
Stock Repurchases — — — — — —
Net Cash from Financing Activities $7.1M $10.2M $1.1M $8.1K $22.5M $1.3M
Net Change in Cash — — — $-8.9M $18.1M $816.4K
Free Cash Flow $-6.2M $-8.1M $-9.0M $-8.9M $-4.4M —